We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.76%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
26
Xencor
XNCR
$1.46B
$21.4M 0.19%
872,072
– –
HALO icon
27
Halozyme
HALO
$9.88B
$20.9M 0.19%
1,731,057
-107,000
-6% -$1.09M
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$20.1M 0.18%
2,475,515
– –
BLUE
29
DELISTED
bluebird bio
BLUE
$19.9M 0.18%
22,692
– –
MRUS
30
DELISTED
Merus
MRUS
$19.4M 0.18%
1,160,014
+37,155
+3% +$353K
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$18.8M 0.17%
4,055,876
– –
NTLA icon
32
Intellia Therapeutics
NTLA
$1.52B
$18.1M 0.16%
1,062,120
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$18M 0.16%
51,625
+96
+0.2% +$25.4K
DSCI
34
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$17.5M 0.16%
3,752,390
– –
LKFT
35
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$16.8M 0.15%
259,894
– –
TGTX icon
36
TG Therapeutics
TGTX
$8.29B
$15.5M 0.14%
2,003,991
– –
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15M 0.14%
2,269,198
– –
ASND icon
38
Ascendis Pharma A/S
ASND
$16.7B
$15M 0.14%
745,521
– –
ARWR icon
39
Arrowhead Research
ARWR
$12B
$13.6M 0.12%
1,856,967
+847,458
+84% +$5.49M
VTAE
40
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$13.3M 0.12%
637,597
– –
ALKS icon
41
Alkermes
ALKS
$8.15B
$11.8M 0.11%
250,251
– –
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$11.4M 0.1%
1,000,000
– –
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$11.3M 0.1%
299,356
– –
DERM
44
DELISTED
Dermira, Inc.
DERM
$11M 0.1%
326,428
– –
AGIO icon
45
Agios Pharmaceuticals
AGIO
$2.1B
$11M 0.1%
207,915
– –
MGNX icon
46
MacroGenics
MGNX
$238M
$10.9M 0.1%
363,676
– –
AIMT
47
DELISTED
Aimmune Therapeutics
AIMT
$10.1M 0.09%
673,908
– –
CFRX
48
DELISTED
ContraFect Corporation
CFRX
$10M 0.09%
+5,057
New +$9.93M
DMTX
49
DELISTED
Dimension Therapeutics, Inc
DMTX
$10M 0.09%
1,251,881
– –
SAGE
50
DELISTED
Sage Therapeutics
SAGE
$9.59M 0.09%
208,328
-15,720
-7% -$640K
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Baker Bros. Advisors held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in ContraFect Corporation worth $10M.

  • Baker Bros. Advisors's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Baker Bros. Advisors's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Baker Bros. Advisors fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 6 in Q3 2016.
  • Baker Bros. Advisors's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.